V-Bio Ventures

📍 Ghent, BE
🏷️ vc
Website besuchen ↗
Investitionsthese

V-Bio Ventures is a life science venture capital fund that focuses on co-creating startups and investing in early- to mid-stage companies with high growth potential. Their core mission is to transform scientific innovation into products that positively impact people’s lives. The firm's investment strategy centers on identifying and supporting companies with differentiated technology addressing unmet needs. They actively seek innovative and transformational technologies with high societal and/or environmental impact potential within the therapeutics sector, encompassing both drug discovery and drug development. V-Bio Ventures leverages its extensive network and sector expertise to provide more than just capital. They aim to be an integral part of the ventures they back, contributing actively to their development. A preferred relationship with VIB, a prominent life science research institute in Belgium, serves as a key source for co-created companies built on VIB-derived innovations. However, they also source deals from research institutes, entrepreneurial initiatives, and spin-outs from established companies across Europe. The firm has a broad investor base that includes financial institutions, governmental bodies, private family offices, and academic institutions. A portion of their funds are supported by InnovFin Equity, backed by the European Union under Horizon 2020 Financial Instruments and the European Fund for Strategic Investments (EFSI), which aims to facilitate financing and implementation of productive investments in the European Union and increase access to financing. Overall, V-Bio Ventures focuses on building a healthier future by investing in companies that leverage great science and empowering talented entrepreneurs. The firm supports its portfolio companies with capital and expertise, facilitating the transformation of scientific innovations into impactful solutions.

Investitionsphase
Early/mid

Bevorzugte Reifephase für die erste Finanzierung.

Sektoren & Themen

Therapeutics, drug discovery, drug development

Thematische Schwerpunkte und Zielmarktsegmente von Interesse.

Ticketgröße
€77.700.000 - €77.850.000

Standard-Finanzierungsbetrag pro Runde.

Outreach & Dossier-Analysen

Verifiziertes E-Mail-Muster

[email protected] | [email protected]

Analysen-Scorecard der Investitionsthese

Unser KI-Analyzer hat Portfolio-Unternehmen gescannt und verifizierte Übereinstimmungen berechnet...

Verifizierte Partnerkontakte freischalten

Finde verifizierte E-Mail-Vorlagen, direkt von der KI verfasste Outreach-Texte und berechne Übereinstimmungen mit 1 Klick.

Kostenloses Konto erstellen

Dauert weniger als 30 Sekunden · Keine Kreditkarte erforderlich